Home › Glioblastoma › Pennsylvania
Glioblastoma clinical trials in Pennsylvania
19 studies for Glioblastoma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07326566Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- Allegheny Health Network, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07195591Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT05432804Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06860594SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Thomas Jefferson University Hospital, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT05303519A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
- Hospital of the University of Pennsylvania, Philadelphia
- University of Pennsylvania, Philadelphia
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06613841Targeted Pediatric High-Grade Glioma Therapy
- Children's Hospital of Philadelphia, Philadelphia
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT02977780WBSI Guided Personalized Delivery of TTFields
- Abramson Cancer Center, Philadelphia
- Penn Medicine, University of Pennsylvania, Philadelphia
Recruiting
Ages 22 and older · All sexes · Updated Aug 6, 2026 · NCT05086497Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
- Penn State Milton S. Hershey Medical Center, Hershey
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Jul 17, 2026 · NCT07225621DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
- UPMC Presbyterian Hospital, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06805305Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Children's Hospital of Philadelphia, Philadelphia
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1
Ages 2 to 21 · All sexes · Updated Jun 11, 2026 · NCT04732065Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- University of Pittsburg Medical Center (UPCM), Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT05283330Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Philadelphia
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- Penn State Milton S. Hershey Medical Center, Hershey
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 27, 2025 · NCT03175224From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.